Salix diarrhea drug works against IBS in Phase III trials

09/14/2009 | American City Business Journals

Salix Pharmaceuticals' rifaximin, a drug for traveler's diarrhea, proved significantly more effective than placebo in treating nonconstipation irritable bowel syndrome and IBS-related bloating during two late-stage trials. Salix plans to seek FDA approval to promote rifaximin for IBS.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI